Bifunctional $^{64}$Cu-labelled macrobicyclic cage amine isothiocyanates for immuno-positron emission tomography

Brett M. Paterson,*a Gojko Buncic,a Lachlan E. McInnes,a Peter Roselt,b Carleen Cullinane,b,c David S. Binns,d Charmaine M. Jeffery,e Roger I. Price,e,f Rodney J. Hicks*c,d and Paul S. Donnelly*a

a School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC, Australia. Email: brettp@unimelb.edu.au; pauld@unimelb.edu.au

b Research Division, Peter MacCallum Cancer Centre, St Andrews Pl, East Melbourne, VIC, Australia.

c The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia. Email: Rod.Hicks@petermac.org

d Centre for Cancer Imaging, Peter MacCallum Cancer Centre, St Andrews Pl, East Melbourne, VIC, Australia

e Department of Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

f School of Physics, The University of Western Australia, Nedlands, WA, Australia.

*To whom correspondence should be addressed.

Figure S1: $^1$H NMR spectrum of [Mg(CH$_3$)(p-NCS-Ph)sar][CF$_3$SO$_3$]$_2$ .................................................2
Figure S2: $^1$H NMR spectrum of [Mg(CH$_3$)(NCS-OEG)sar][CF$_3$SO$_3$]$_2$ ....................................................2
Figure S3: Structure of the water soluble bis(thiosemicarbazone) Na[H$_2$L].................................................2
Figure S4: Section of interest of an absorbance spectrum (around 280 nm) of a solution containing Trastuzumab (25 µL) in 50 mM MOPS buffer (3000 µL, pH 7.1). .................................3
Figure S5: Section of interest of overlayed absorbance spectra (around 280 nm) of solutions formed as a result of titration of (CH$_3$)(p-NCS-Ph)sar-trastuzumab (4 µL each aliquot) into 50 mM MOPS buffer (918 µL) ........................................................................3
Figure S6: Section of interest of overlayed absorbance spectra (around 460 nm) of the solutions used in determination of ligand to antibody ratio.........................................................4
**Figure S1:** $^1$H NMR spectrum of $[\text{Mg}(\text{CH}_3)(\rho\text{-NCS-Ph})\text{sar}](\text{CF}_3\text{SO}_3)_2$

**Figure S2:** $^1$H NMR spectrum of $[\text{Mg}(\text{CH}_3)(\text{NCS-OEG})\text{sar}](\text{CF}_3\text{SO}_3)_2$

**Figure S3:** Structure of the water soluble bis(thiosemicarbazone) Na[H$_2$L]
Figure S4: Section of interest of an absorbance spectrum (around 280 nm) of a solution containing Trastuzumab (25 μL) in 50 mM MOPS buffer (3000 μL, pH 7.1).

Figure S5: Section of interest of overlayed absorbance spectra (around 280 nm) of solutions formed as a result of titration of (CH$_3$)(p-NCS-Ph)sar-trastuzumab (4 μL each aliquot) into 50 mM MOPS buffer (918 μL).
Figure S6: Section of interest of overlayed absorbance spectra (around 460 nm) of the solutions used in determination of ligand to antibody ratio.